THE Industrial Development Corporation (IDC) and Jijia (Beijing) International Medical Technology have signed a joint venture agreement for the development of ZAMVAX Limited, a vaccine manufacturing plant. IDC Chief Executive Officer Cornwell Muleya says under the joint venture, IDC will hold a 60 percent shareholding, while Jijia will hold 40 percent. Meanwhile, Jijia General Manager Su Yong Lin says the partnership is more than just an investment, as it is about supporting Zambia’s healthcare sector and improving health security across Africa. Speaking at the signing ceremony, Monday, Muleya said the total project investment was around US$213 million, with phase one costing US$24.13 million and phase two costing US$189 million. “Every year, Zambia has been faced with some epidemics of cholera,...